- Home
- NPCE vs ETON Comparison
NPCE vs ETON Comparison
Compare NPCE & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- ETON
- Stock Information
- Founded
- NPCE 1997
- ETON 2017
- Country
- NPCE United States
- ETON United States
- Employees
- NPCE N/A
- ETON N/A
- Industry
- NPCE Medical Specialities
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- ETON Health Care
- Exchange
- NPCE Nasdaq
- ETON Nasdaq
- Market Cap
- NPCE 424.1M
- ETON 428.5M
- IPO Year
- NPCE 2021
- ETON 2018
- Fundamental
- Price
- NPCE $10.39
- ETON $14.99
- Analyst Decision
- NPCE Buy
- ETON Strong Buy
- Analyst Count
- NPCE 7
- ETON 3
- Target Price
- NPCE $15.14
- ETON $29.67
- AVG Volume (30 Days)
- NPCE 412.6K
- ETON 605.6K
- Earning Date
- NPCE 08-12-2025
- ETON 08-07-2025
- Dividend Yield
- NPCE N/A
- ETON N/A
- EPS Growth
- NPCE N/A
- ETON N/A
- EPS
- NPCE N/A
- ETON N/A
- Revenue
- NPCE $84,306,000.00
- ETON $48,327,000.00
- Revenue This Year
- NPCE $21.00
- ETON $103.21
- Revenue Next Year
- NPCE $11.81
- ETON $51.34
- P/E Ratio
- NPCE N/A
- ETON N/A
- Revenue Growth
- NPCE 22.05
- ETON 40.88
- 52 Week Low
- NPCE $5.45
- ETON $3.22
- 52 Week High
- NPCE $18.98
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- NPCE 36.54
- ETON 43.76
- Support Level
- NPCE $10.10
- ETON $13.51
- Resistance Level
- NPCE $11.53
- ETON $14.70
- Average True Range (ATR)
- NPCE 0.66
- ETON 0.74
- MACD
- NPCE -0.00
- ETON 0.12
- Stochastic Oscillator
- NPCE 28.15
- ETON 88.30
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.